59 related articles for article (PubMed ID: 24869930)
1. Prognostic impact of pretreatment cell-free DNA concentration in newly diagnosed peripheral T-cell lymphomas.
Fardella E; Zanirato G; Magni M; Caldarelli N; Chiappella A; Dodero A; Ljevar S; Orsucci L; Re A; Usai SV; Stefoni V; Castellino C; Rossi FG; Pinto A; Carniti C; Corradini P
Br J Haematol; 2024 May; 204(5):1752-1756. PubMed ID: 38176400
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
Coiffier B; Federico M; Caballero D; Dearden C; Morschhauser F; Jäger U; Trümper L; Zucca E; Gomes da Silva M; Pettengell R; Weidmann E; d'Amore F; Tilly H; Zinzani PL
Cancer Treat Rev; 2014 Oct; 40(9):1080-8. PubMed ID: 25199959
[TBL] [Abstract][Full Text] [Related]
3. Current management of peripheral T-cell lymphomas.
Gooptu M; Rhoades R; Pro B
Cancer Treat Res; 2015; 165():289-303. PubMed ID: 25655615
[TBL] [Abstract][Full Text] [Related]
4. Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.
Horwitz S; Coiffier B; Foss F; Prince HM; Sokol L; Greenwood M; Caballero D; Morschhauser F; Pinter-Brown L; Iyer SP; Shustov A; Nichols J; Balser J; Balser B; Pro B
Ann Oncol; 2015 Apr; 26(4):774-779. PubMed ID: 25605745
[TBL] [Abstract][Full Text] [Related]
5. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
Foss F; Advani R; Duvic M; Hymes KB; Intragumtornchai T; Lekhakula A; Shpilberg O; Lerner A; Belt RJ; Jacobsen ED; Laurent G; Ben-Yehuda D; Beylot-Barry M; Hillen U; Knoblauch P; Bhat G; Chawla S; Allen LF; Pohlman B
Br J Haematol; 2015 Mar; 168(6):811-9. PubMed ID: 25404094
[TBL] [Abstract][Full Text] [Related]
6. How to Sequence Therapies in Peripheral T Cell Lymphoma.
Wudhikarn K; Bennani NN
Curr Treat Options Oncol; 2021 Jul; 22(9):74. PubMed ID: 34213653
[TBL] [Abstract][Full Text] [Related]
7. What's new in peripheral T-cell lymphomas.
Luminari S; Skrypets T
Hematol Oncol; 2021 Jun; 39 Suppl 1(Suppl 1):52-60. PubMed ID: 34105820
[TBL] [Abstract][Full Text] [Related]
8. Controversies in the Treatment of Peripheral T-cell Lymphoma.
Bachy E; Broccoli A; Dearden C; de Leval L; Gaulard P; Koch R; Morschhauser F; Trümper L; Zinzani PL
Hemasphere; 2020 Oct; 4(5):e461. PubMed ID: 33062943
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of FDG-PET/CT in determining upfront autologous stem cell transplantation for the treatment of peripheral T cell lymphomas.
Ahn SY; Jung SY; Jung SH; Ahn JS; Lee JJ; Kim HJ; Kang SR; Han YH; Kwak JY; Yhim HY; Yang DH
Ann Hematol; 2020 Jan; 99(1):83-91. PubMed ID: 31807859
[TBL] [Abstract][Full Text] [Related]
10. Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma.
Mehta-Shah N; Ito K; Bantilan K; Moskowitz AJ; Sauter C; Horwitz SM; Schöder H
Blood Adv; 2019 Jan; 3(2):187-197. PubMed ID: 30670535
[TBL] [Abstract][Full Text] [Related]
11. Peripheral T-cell lymphoma - are we making progress?
Khan N; Ozkaya N; Moskowitz A; Dogan A; Horwitz S
Best Pract Res Clin Haematol; 2018 Sep; 31(3):306-314. PubMed ID: 30213401
[TBL] [Abstract][Full Text] [Related]
12. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas.
Barrington SF; Kluge R
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(Suppl 1):97-110. PubMed ID: 28411336
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of interim and end-of-treatment PET/CT in patients with newly diagnosed peripheral T-cell lymphoma.
Ham JS; Kim SJ; Choi JY; Hyun SH; Choi SK; Kim HS; Lim SH; Lee JY; Jung SH; Ko YH; Kim WS
Blood Cancer J; 2016 Feb; 6(2):e395. PubMed ID: 26871713
[No Abstract] [Full Text] [Related]
14. Prognostic significance of interim PET/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma.
Jung SH; Ahn JS; Kim YK; Kweon SS; Min JJ; Bom HS; Kim HJ; Chae YS; Moon JH; Sohn SK; Lee SW; Byun BH; Do YR; Lee JJ; Yang DH
BMC Cancer; 2015 Mar; 15():198. PubMed ID: 25879747
[TBL] [Abstract][Full Text] [Related]
15. Positron Emission Tomography (PET) in Oncology.
Gallamini A; Zwarthoed C; Borra A
Cancers (Basel); 2014 Sep; 6(4):1821-89. PubMed ID: 25268160
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma.
Pellegrini C; Argnani L; Broccoli A; Stefoni V; Derenzini E; Gandolfi L; Casadei B; Maglie R; Pileri S; Zinzani PL
Oncologist; 2014 Jul; 19(7):746-50. PubMed ID: 24869930
[TBL] [Abstract][Full Text] [Related]
17. Post-therapy ¹⁸F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma.
Tomita N; Hattori Y; Fujisawa S; Hashimoto C; Taguchi J; Takasaki H; Sakai R; Tateishi U; Ishigatsubo Y
Ann Hematol; 2015 Mar; 94(3):431-6. PubMed ID: 25338967
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
